Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study

- Shapiro, Jeremy D., Thavaneswaran, Subotheni, Tebbutt, Niall C., Price, Timothy J., Khasraw, Mustafa, Van Hazel, Guy A., Waring, Paul M., Tejpar, Sabine, Simes, John, Gebski, Val J., Desai, Jayesh, Segelov, Eva, Underhill, Craig R., Robledo, Kristy P., Karapetis, Chistos S., Day, Fiona L., Nott, Louise M., Jefford, Michael, Chantrill, Lorraine A., Pavlakis, Nick

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone

- Lee, Chee Khoon, Gebski, Val J., Coates, Alan S., Veillard, Anne-Sophie, Harvey, Vernon, Tattersall, Martin H. N., Byrne, Michael J., Brigham, Brian, Forbes, John, Simes, R. John

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

- Tebbutt, Niall C., Wilson, Kate, Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Gebski, Val J., Cummins, Michelle M., Zannino, Dianna, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P.